Premium
Front Cover: Translating Immunopeptidomics to Immunotherapy‐Decision‐Making for Patient and Personalized Target Selection
Author(s) -
Fritsche Jens,
Rakitsch Barbara,
Hoffgaard Franziska,
Römer Michael,
Schuster Heiko,
Kowalewski Daniel J.,
Priemer Martin,
StosZweifel Vlatka,
Hörzer Helen,
Satelli Arun,
Sonntag Annika,
Goldfinger Valentina,
Song Colette,
Mahr Andrea,
Ott Martina,
Schoor Oliver,
Weinschenk Toni
Publication year - 2018
Publication title -
proteomics
Language(s) - English
Resource type - Reports
SCImago Journal Rank - 1.26
H-Index - 167
eISSN - 1615-9861
pISSN - 1615-9853
DOI - 10.1002/pmic.201870101
Subject(s) - t cell receptor , immunotherapy , front cover , cancer immunotherapy , peptide , computational biology , cancer research , medicine , chemistry , biology , cancer , immunology , t cell , immune system , biochemistry , cover (algebra) , mechanical engineering , engineering
DOI: 10.1002/pmic.201700284 Translation from immunopeptidomics to HLA peptide target to TCR lead to cancer immunotherapy. Cancer antigen Ag007‐01 (blue) bound to HLA‐A*02:01 (red) recognized by ACTengine™ IMA201 T‐cell receptor (green) is currently investigated in ACT trial NCT03247309. Ag007‐01 is detected on squamous NSCLC by LC‐MS/MS shown as heatmap (m/z vs retention time). This is reported in article number 1700284 by Fritsche et al. TCR homology model (Modeller, UCSF) and peptide‐MHC crystal structure rendered with Chimera (UCSF) by Mathias Ferber.